Please login to the form below

Not currently logged in
Email:
Password:

Novartis 'reviewing options' for Alcon division

Possible sale or spin-off in store for eyecare unit as firm reports Q4 operating loss of $132m
Novartis

Novartis said today it is considering a spin-off for its struggling Alcon eyecare unit, but stressed that no decisions have been made and a range of options are on the table.

A review of Alcon's operations will take place over the course of 2017, but any decision will apply only to the devices portion of the business - such as surgical devices and contact lenses - as ophthalmic drugs have been integrated into the broader pharma business, said Novartis.

"The review will explore all options, ranging from retaining the business to separation via a capital markets transaction" such as an initial public offering (IPO) or spin-off, said the company in its fourth quarter 2016 results statement.

Novartis has been mulling a possible sale or spin-off of Alcon for some time, as the unit has been grappling with a lacklustre outflow of new products and inconsistent supply levels and customer service that has hit sales.

Last year, chief executive Joe Jimenez set a deadline for Alcon to get sales back on track by the end of 2016, but fourth quarter sales were flat - even though the contact lenses business delivered a third quarter of consecutive growth - and the division made an operating loss of $132m.

All told, Novartis reported a 2% decline in sales to $12.52bn in the quarter, with Alcon down 3% to $5.8bn and the branded pharma business also down 3% to $8.3bn. Only the Sandoz generics division stayed in positive territory, with a 2% rise in sales to $2.6bn spurred by growth in biosimilars, which matched expectations of $1bn for the full-year.

The company is expecting 2017 to continue to be pressured as former top-selling cancer drug Glivec/Gleevec (imatinib) continues to face generic competition, with a return to growth next year driven by new products.

Among these, psoriasis therapy Cosentyx (secukinumab) entered the blockbuster category in 2016 with sales of $1.1bn - setting it on course to reach Novartis' target of $4-5bn in peak sales - while chronic heart failure therapy Entresto (sacubitril and valsartan) continued its slow growth to reach $170m.

Entresto is expected to gather momentum this year - with prescriptions set to triple according to Jimenez - as the salesforce is now fully in place and reimbursement coverage in the US is more comprehensive.

The CEO said that Novartis would continue its policy of bolt-on acquisitions to boost the pipeline, and would also start a buyback of $5bn-worth in shares.

In 2016 the company made "major strides in advancing our pipeline, executing our bolt-on M&A strategy and implementing our new focused organisation," he added.

Article by
Phil Taylor

25th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics